When will the FDA approve Intellia Therapeutics' lonvo-z? | PredictPedia

Price ChartMatched Markets Price Graph

3 markets tracked

When will the FDA approve Lonvoguran Ziclumeran (lonvo-z) for Hereditary Angioedema? (Before 2028)

No data available

Single-Platform Markets(3)

Market	Platform	Price
When will the FDA approve Lonvoguran Ziclumeran (lonvo-z) for Hereditary Angioedema? (Before 2028)	Kalshi	65%
When will the FDA approve Lonvoguran Ziclumeran (lonvo-z) for Hereditary Angioedema? (Before October 2027)	Kalshi	45%
When will the FDA approve Lonvoguran Ziclumeran (lonvo-z) for Hereditary Angioedema? (Before July 2027)	Kalshi	31%

Custom AI Analysis Prompt

Tap to expand

Open in:ChatGPT Claude Gemini Grok DeepSeek

**Role:** Expert Prediction Market Analyst & Trader
**Objective:** Analyze the provided betting market data to deliver actionable insights, identify mispricings, and perform scenario analysis.
**Current Date:** Friday, April 17, 2026
**Context:** Prediction markets (Polymarket/Kalshi) are binary option markets where price (1-99) equals implied probability (1%-99%).

---

## 1. Event Snapshot
**Event:** When will the FDA approve Intellia Therapeutics' lonvo-z?
**Category:** Science and Technology | **Status:** active
**Resolution Date:** N/A (Unknown)
**Time Pressure:** Unknown

**Description:** Lonvoguran Ziclumeran (lonvo-z) for Hereditary Angioedema

If the FDA approves Lonvoguran Ziclumeran, lonvo-z, for Hereditary Angioedema for marketing before X 1, Y then the market resolves to Yes. Early close condition: This market will close and expire early if the event occurs. This market will close and expire early if the event occurs.

**Resolution Criteria (Sample):**
"If the FDA approves Lonvoguran Ziclumeran (lonvo-z) for Hereditary Angioedema for marketing before Jan 1, 2028, then the market resolves to Yes. Early close condition: This market will close and expire early if the event occurs."

## 2. Market liquidity & Volume
* **Total Volume:** $0
* **Total Liquidity:** $0
* **Activity Level:** Low Activity (Vol/Liq Ratio: 0.00)

## 3. Market Data (Prices & Odds)
### 1. When will the FDA approve Lonvoguran Ziclumeran (lonvo-z) for Hereditary Angioedema? (Before 2028)
- **Kalshi** (End: Jan 8, 2028): Vol $0
  DATA: [Yes: 65.0% (0.0%)] | [No: 35.0% (0.0%)]

### 2. When will the FDA approve Lonvoguran Ziclumeran (lonvo-z) for Hereditary Angioedema? (Before October 2027)
- **Kalshi** (End: Oct 8, 2027): Vol $0
  DATA: [Yes: 45.0% (0.0%)] | [No: 55.0% (0.0%)]

### 3. When will the FDA approve Lonvoguran Ziclumeran (lonvo-z) for Hereditary Angioedema? (Before July 2027)
- **Kalshi** (End: Jul 8, 2027): Vol $0
  DATA: [Yes: 31.0% (0.0%)] | [No: 69.0% (0.0%)]

---

## Analysis Instructions
Please provide a structured analysis using the following template:

### 1. Executive Summary
*   **Verdict:** [Most Likely Outcome]
*   **Confidence:** [0-100]%
*   **Timeframe:** [Immediate / Short-term / Long-term]
*   **Actionable Trade:** [Buy YES / Buy NO / Stay Away] (Include entry price target if applicable)
*   **Rationale:** 2-sentence summary of the core thesis.

### 2. Scenario Analysis
*   **Bull Case (Why YES goes up):** List specific catalysts or data points.
*   **Bear Case (Why YES goes down):** List specifics.
*   **Invalidation Point:** What happens to prove your thesis wrong?

### 3. Market Mechanics & Risks
*   **Liquidity/Volume Analysis:** Is the market efficient? Is it easy to exit?
*   **Cross-Platform Arbitrage:** (If applicable) Is the spread tradeable after fees?
*   **Time Decay:** How does time passing affect this position?

### 4. Signal Scores (0-100)
*   **Momentum:** [Score] (Price trend & velocity)
*   **Conviction:** [Score] (Volume backing the move)
*   **Information Edge:** [Score] (Likelihood of non-public info affecting price)
*   **Risk/Reward:** [Score] (Potential upside vs downside)

**Constraints:**
- Be direct and objective.
- Use bullet points for readability.
- If data is conflicting or insufficient, explicitly state "Low Confidence".

Tap text to select all

Market Insights

Average Yes Price

47¢

Kalshi

Arbitrage Opps

Cross-Platform

Embed Widget

Add this market to your website

Volume

Platforms

HTML

<iframe src="https://predictpedia.com/embed/daEJ5x" width="400" height="160" frameborder="0" style="border-radius: 8px; max-width: 100%;" title="When will the FDA approve Intellia Therapeutics' lonvo-z?"></iframe>

Trade This Market

Trade on Kalshi

When will the FDA approve Intellia Therapeutics' lonvo-z?

When will the FDA approve Intellia Therapeutics' lonvo-z?

Platform StatsQuick Platform Comparison

Price ChartMatched Markets Price Graph

When will the FDA approve Lonvoguran Ziclumeran (lonvo-z) for Hereditary Angioedema? (Before 2028)

AI Analysis

About This Event

Custom AI Analysis Prompt

Educational Context

Events (1)

When will the FDA approve Intellia Therapeutics' lonvo-z?

Markets (3)

When will the FDA approve Lonvoguran Ziclumeran (lonvo-z) for Hereditary Angioedema? (Before 2028)

When will the FDA approve Lonvoguran Ziclumeran (lonvo-z) for Hereditary Angioedema? (Before 2028)

When will the FDA approve Lonvoguran Ziclumeran (lonvo-z) for Hereditary Angioedema? (Before October 2027)

When will the FDA approve Lonvoguran Ziclumeran (lonvo-z) for Hereditary Angioedema? (Before October 2027)

When will the FDA approve Lonvoguran Ziclumeran (lonvo-z) for Hereditary Angioedema? (Before July 2027)

When will the FDA approve Lonvoguran Ziclumeran (lonvo-z) for Hereditary Angioedema? (Before July 2027)

Related News & Context

Discussion

Market Insights

Share

Embed Widget

Trade This Market

Price ChartMatched Markets Price Graph

When will the FDA approve Lonvoguran Ziclumeran (lonvo-z) for Hereditary Angioedema? (Before 2028)

Custom AI Analysis Prompt

When will the FDA approve Intellia Therapeutics' lonvo-z?

When will the FDA approve Lonvoguran Ziclumeran (lonvo-z) for Hereditary Angioedema? (Before 2028)

When will the FDA approve Lonvoguran Ziclumeran (lonvo-z) for Hereditary Angioedema? (Before 2028)

When will the FDA approve Lonvoguran Ziclumeran (lonvo-z) for Hereditary Angioedema? (Before October 2027)

When will the FDA approve Lonvoguran Ziclumeran (lonvo-z) for Hereditary Angioedema? (Before October 2027)

When will the FDA approve Lonvoguran Ziclumeran (lonvo-z) for Hereditary Angioedema? (Before July 2027)

When will the FDA approve Lonvoguran Ziclumeran (lonvo-z) for Hereditary Angioedema? (Before July 2027)

Related News & Context

Discussion

Share

Embed Widget